Ardelius Boan
Nurse Practitioner · Stanford, CANPI 1790147270
Payments from drug & device makers
Across 101 payments — averaging $21.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$959
- Neurocrine Biosciences, Inc.$284
- Pfizer$205
- SK Life Science, Inc.$97
- Lilly USA, LLC$76
- Eisai Inc.$64
- plus $475 from 14 others
What the payments were for
- Food & beverage$2,161100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 40 | $959 |
| Neurocrine Biosciences, Inc. | 15 | $284 |
| Pfizer | 13 | $205 |
| SK Life Science, Inc. | 4 | $97 |
| Lilly USA, LLC | 4 | $76 |
| Eisai Inc. | 3 | $64 |
| Genentech USA, Inc. | 3 | $64 |
| Merz Pharmaceuticals, LLC | 2 | $56 |
| Jazz Pharmaceuticals Inc. | 2 | $53 |
| Amneal Pharmaceuticals LLC | 3 | $50 |
| Teva Pharmaceuticals USA, Inc. | 2 | $41 |
| AstraZeneca | 2 | $40 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Argenx US, Inc. | 1 | $24 |
| Novartis | 1 | $23 |
| Amgen | 1 | $23 |
| Scilex Pharmaceuticals Inc. | 1 | $21 |
| UCB, Inc. | 1 | $19 |
| Tanabe Pharma America, Inc. | 1 | $17 |
| Banner Life Sciences, LLC | 1 | $16 |
How this compares
$2,161 in reported general payments places this provider in the 85th percentile of 6,779 nurse practitioner providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Carbidopa-LevodopaCarbidopa/Levodopa | 49 | $1,541 |
| Levetiracetam | 32 | $873 |
| Valproic Acid | 11 | $764 |
| Memantine Hcl | 15 | $493 |
| Celecoxib | 15 | $372 |
| Gabapentin | 23 | $306 |
| Donepezil Hcl | 35 | $217 |
| Doxepin Hcl | 11 | $208 |
| Lamotrigine | 12 | $141 |
| Primidone | 11 | $104 |
| Quetiapine Fumarate | 15 | $68 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in Stanford
- Rhonda HewittStanford$917K
- Hamta ZareStanford$428K
- Theresa Mallick-SearleStanford$193K
- Martina SpeightStanford$170K
- Helen ShihStanford$104K
- Connie WolfordStanford$69K
- Michelle GapayStanford$37K
- Elaine JangStanford$32K
- Linda TrinhIrvine$899K
- Denise SinagaNorthridge$728K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.